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Abstract
Background: Randomized controlled trials (RCTs) are the cornerstone of  modern medical research, and their reporting may not always be optimal. The 
Consolidated Standards of  Reporting Trials (CONSORT) statement is an evidence-based means to improve the quality of  RCTs’ reporting by providing a checklist 
of  recommended items.
The aim of  this study was to assess the reporting quality of  published RCTs on the restless legs syndrome (RLS), based on a checklist arising from the CONSORT statement.
Methods: Medical electronic databases were searched for RCTs involving patients with RLS. Inclusion criteria were follows: articles must have been published in English 
and RLS patients must have been randomized into a minimum of  two treatment cohorts of  different medicinal orientations. CONSORT-recommended items were marked 
as “reported” or “not reported,” and an overall CONSORT compliance metric was calculated. Comparisons among different time periods, CONSORT-endorsing and 
non-endorsing, and different levels of  impact factor journals were made.
Results: Fifty-four eligible trials, published in 21 different scientific journals, were found. The average CONSORT compliance score was 56.6% (23.68–84.21%). 
CONSORT-endorsing journals had a mean CONSORT compliance of  58.47%, whereas non-endorsing journals had a mean CONSORT compliance of  50.4%. 
The median CONSORT compliance for articles published in low- (IF<2), medium- (IF 2-7), and high-ranked (IF>7) journals was 52.63, 56.57, and 59.21%, 
 respectively. Only 14 of  the 38 CONSORT items (36.8%) were reported in >75% of  the articles.
Discussion: This study shows that the reporting of  RLS-related RCTs is suboptimal, regardless of  the time period, the quality of  the publishing journal, and the endorsing 
or non- endorsing of  the CONSORT statement.
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Citation: Rikos D, Dardiotis E, Aloizou A-M, Siokas V, Zintzaras E, Hadjigeorgiou GM. Reporting Quality of  Randomized Controlled Trials in Restless Legs 
Syndrome Based on the CONSORT Statement. Tremor Other Hyperkinet Mov. 2019; 9. doi:10.7916/d8-0f2v-aq62
Articles
Reporting Quality of Randomized Controlled Trials in Restless Legs 
Syndrome Based on the CONSORT Statement
Dimitrios Rikos1,2†, Efthimios Dardiotis1*†, Athina-Maria Aloizou1, Vasileios Siokas1, Elias Zintzaras2,3 & Georgios M. Hadjigeorgiou1,4
1Department of Neurology, University of Thessaly, University Hospital of Larissa, Larissa, Greece 2Department of Biomathematics, University of Thessaly 
School of Medicine, Larissa, Greece 3The Institute for Clinical Research & Health Policy Studies, Tufts Medical Center and Pharmacology & Drug 
Development Program, Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA, USA 4Department of Neurology, 
Medical School, University of Cyprus, Nicosia, Cyprus
Introduction
In the era of  evidence-based medicine, randomized controlled trials 
(RCTs) are the highest ranked means of  research and are considered as 
“the most powerful tool in modern clinical research.”1 Even if  recent 
research methods, such as meta-analyses and umbrella meta-analyses, 
provide more accurate data, the quality of  RCTs remains central, as they 
represent the structural element of  the aforementioned research method-
ologies. The process of  randomization in clinical trials guarantees that the 
significant findings in the group comparisons regarding the matter under 
examination can be accredited to the intervention and not to other con-
founding factors,2 thus minimizing bias. However, available information 
in biomedical journals may be concealing a wide range of  biases, such as 
publication, selection, and funding biases.3,4,5 It is crucial for readers and 
other researchers to be aware of  the quality standards of  RCTs so as to 
properly assess their strong and weak points.6,7
It is clear that evidence-based healthcare relies, among others, on the 
quality assessment of  RCTs. The reporting of  RCTs, as a type of  medical 
literature, has in general got a certain form and adopted a basic structure 
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that is more or less used by the majority of  authors. However, several 
strategic methodological characteristics may be overlooked in published 
reports and, therefore, the assessment of  reporting quality may be used 
as a surrogate for trial quality.8 A trial with inadequate reporting quality 
may be misclassified, while an unclear and inaccurate description may 
be attempting to conceal erroneous methods.7,9,10
Time and time again, evidence has stated that the reporting quality of  
RCTs is not optimal.11,12 Addressing these concerns, at the end of  the 20th 
century, an international group of  trial methodology experts, including 
statisticians, epidemiologists, science journal editors, and clinical trialists, 
created the Consolidated Standards of  Reporting Trials (CONSORT) 
Statement, which was last updated in March 2010.This statement is an 
evidence-based set of  recommendations, including a checklist and a flow 
diagram, for the reporting of  RCTs; its aim is to promote the thorough 
and transparent reporting of  trials while simultaneously assisting in their 
critical evaluation and understanding.11 Recommendations concern the 
title, introduction, methods, results, and other information that should be 
reported and cover virtually every aspect of  conducting an RCT accord-
ing to Good Clinical Practice. Separate items cover the methodology of  
the trials (randomization methods, blinding, etc.), the statistical analysis, 
the outcomes, as well as other information like the funding source and the 
online access of  the study protocol. CONSORT stresses the importance 
of  integrality, preciseness, and transparency of  reporting, which are, all in 
all, indicative of  the actual trial plan and conduct.13
A number of  publications have examined the reporting quality of  
RCTs in several subspecialties of  medicine.14,15,16,17,18,19,20,21 In a recent 
study by our team, concerning multiple sclerosis, the mean CONSORT 
compliance was found to be considerably low, since only 30% of  the 
studies reported more than 75% of  the CONSORT items.21 Similar 
studies in polycystic ovary syndrome, urology, and other surgical special-
ties also found the CONSORT compliance to be suboptimal,16,20 reflect-
ing the intersectionality of  the issue in the medical field.
Restless legs syndrome (RLS) is a relatively common neurological dis-
ease,22,23 which can be primary or secondary.24, 25, 26 The unpleasant sensation 
of  RLS and the subsequent sleep disturbance have a significant socioeco-
nomic impact on patients.27, 28 Following the ongoing series of  reporting 
quality analyses in neurological diseases, in the present study, we analyzed 
the reporting quality of  RCTs involving patients with RLS (primary or sec-
ondary), using the items of  the revised CONSORT 2010 statement check-
list.13 The period covered by this report extends from 1998 to 2017.
Methods
Data sources and search strategies
We searched the PubMed database for RCTs on patients with RLS pub-
lished between the January 1, 1998 and December 31, 2017. As a search 
criterion, the phrase “Restless Legs Syndrome” or “RLS” or “Willis–
Ekbom disease” was used. We used the “Randomized Controlled Trial” 
type of  article, “English” language, and “Humans” for species as filters.
Eligibility of studies
Trials were eligible for inclusion if  the participants had been ran-
domly assigned to at least two medicinal treatment arms (including 
iron and vitamin supplementation) and included patients with RLS 
regardless of  the etiology (primary or secondary). Reports of  trials 
without RLS-relevant symptoms as end points, dose comparison stud-
ies, those with non-medicinal regimens, and small pilot studies, along-
side any article with information resulting from a previously conducted 
trial (such as post hoc or sub-group analysis and various sub-studies), 
were excluded. Crossover studies were also excluded due to their spe-
cific design.29
Reporting assessment tool
The CONSORT 2010 checklist consists of  25 items, which, along-
side their sub-items, reach a total number of  37 items. This checklist is 
recommended to be used by authors during the reporting of  RCTs to 
promote thorough work and transparency in their presentation. 
Alongside the explanation and elaboration document, CONSORT 
provides instructions for every section of  an RCT article (title, intro-
duction, methods, results, and funding) and covers every aspect of  a 
well-conducted clinical trial (Supplementary File 2). We have included 
an additional item (No 13), whether an article included a participant 
flow diagram or not, in order to pertain to the authors’ (strong) recom-
mendation of  using one. The CONSORT explanation and elabora-
tion document (available at the CONSORT website) was used to 
guide our evaluation process. Out of  the total 54 eligible trials, 28 
were published before 2010 and 26 were published after 2010, with 
2010 being the year when the CONSORT Statement was revised. We 
used the revised CONSORT version for all the extracted articles. The 
full CONSORT checklist can be accessed online at http://www.con-
sort-statement.org.
Evaluation – analysis
During the evaluation process, each author reviewed the selected 
articles one by one and assigned a positive (“yes”) or a negative (“no”) 
response to each CONSORT item, according to whether it was 
reported or not. Additionally, the following procedures were followed: 
(1) all of  the checklist items were searched for into the published trials 
in terms of  whether they were reported, and not if  they were actually 
performed during the trial. In cases where a methodology followed by 
the trials’ authors was insinuated in the results or other sources, but 
there was no lucid reference in the article (or the supplementary files), 
the CONSORT item was marked as “non-reported.” For example, if  a 
trial stated on its title that it is a “double-blinded” trial but there was no 
clear reference in the methodology section as for how it was blinded, 
the respective items were checked as “non-reported.” (2) In cases where 
it was not obvious whether the criterion of  reporting was met, after 
consensus among all authors, the item was assigned a negative mark 
(non-reported), since they may conceal important information. (3) In 
cases where a procedure of  the trial was not mentioned in the main 
manuscript of  the trial but there was a reference to it in a supplemen-
tary file which addressed this information, the procedure was consid-
ered as adequately reported. This rule was not applied to item 8a, 
where the CONSORT Explanation and Elaboration Document specif-
ically requires that “information on the process of  randomization is 
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included in the body of  the main article and not as a separate supple-
mentary file; where it can be missed by the reader.”30 Evaluation was 
made by two independent authors (D.R. and E.D.), and discrepancies 
were resolved by consensus among all authors. The articles were 
divided into three groups depending on the time of  publication: from 
1998 to 2004, from 2005 to 2009, and from 2010 to 2017. We also 
categorized the reported items into five groups as follows: (1) Title/
Abstract and Introduction, (2) Methods, (3) Results, (4) Discussion, and 
(5) Other information.
The basic quality-of-reporting metric was the “CONSORT compli-
ance,” meaning the percentage of  the 38 CONSORT items that each 
article addressed. We calculated the greater than 75% compliance with 
the CONSORT statement items, as compliance with the CONSORT 
items to the extent of  greater than 75% was considered an adequate 
cutoff  in a number of  other studies.14,31 This metric was considered 
as a measure of  each article’s reporting quality. It must be noted at 
this point that items 3b (changes to methods), 6b (changes to trial 
 outcomes), 7b (interim analyses and stopping guidelines), and 14b 
(why the trial had to be ended or terminated) are items that were not 
applicable in most of  the trials. Item 17b (effect sizes of  binary out-
comes), though an important item in RCTs in general, may not be 
applicable to RLS trials where the most commonly used outcomes are 
categorical (e.g., IRLS SG score and polysomnographic data); hence, it 
is also justifiably under-reported. By removing the five aforementioned 
items, a total of  86.6% compliance was considered to be the maximum 
that an article could reach.
The comparison of  the >75% compliance among the different time 
period groups was made using the Pearson chi-square statistic for a 2×3 
table. We calculated the percentage of  items per group (title and 
abstract, methods, results, discussion, and other) that was reported in at 
least 75% of  the articles for the total and individual time periods. This 
metric is an indicator of  which CONSORT items were adequately 
reported or under-reported by the articles in comparison to the compli-
ance, which is a measure of  each article’s reporting quality. We further 
calculated the median CONSORT compliance of  the articles published 
in journals with a current impact factor greater than 7, between 2 and 7, 
and lower than 2, and additionally performed a Kruskal–Wallis 
non-parametric test to compare the three groups. Journal impact factor 
was accessed through the Thomson Reuters Journal Citation Reports 
website,32,33 and all statistical analyses were made using the IBM SPSS 
v.21 package.
Results
The evaluation process was carried out in four steps, as can be 
seen in the search flow chart (Figure 1). Initial search for entries 
meeting the set criteria returned 307 related articles, whose titles 
were scrutinized. One hundred and eighty articles were excluded 
due to irrelevance, use of  non-medicinal intervention (behavioral 
treatment, exercise, herbal), or not referring to randomized trials. 
The abstracts of  the remaining 127 articles were reviewed and an 
additional 52 articles were excluded for the same reasons. The 
remaining 75 articles were retrieved in full text, 21 of  which were 
found ineligible for reasons explained before, and finally 54 articles 
were included in the study. A list of  these 54 RCTs, which 
included a total of  10,427 randomized patients, can be found in the 
Supplementary file.
Of  the total 54 eligible trials, 9 were published between 1998 and 
2004, 19 between 2005 and 2009, and 26 between 2010 and 2017, 
when the revised CONSORT version had been made available. The 
drugs in comparison against placebo or another active component 
were gabapentin (8 studies), cabergolide (2 studies), bupropion 
(1 study), iron (7 studies), oxycodone (1 study), pergolide (2 studies), 
pramipexole (12 studies), pregabaline (3 studies), ropinirole (9 studies), 
rotigotine (6 studies), sumanirole (1 study), vitamins (1 study), and 
xp13512 (1 study).
Twenty-one different scientific journals hosted the included articles. 
Nine of  them are currently CONSORT-endorsing, corresponding to 
76% (41) of  the articles. The mean CONSORT compliance of  articles 
published in these journals reached 58.47%. The remaining 13 articles, 
published in 12 non-endorsing journals, had a mean CONSORT com-
pliance of  50%. The median CONSORT compliance scores of  articles 
published in low (IF<2), medium (IF 2-7), and high-ranked (IF >7) jour-
nals were 52.63, 56.57, and 59.21%, respectively. These percentages 
were not found to be significantly different (Kruskal-Wallis (K-W) 
p = 0.272).The eligible RCTs were relatively small, with an average 
count of  randomized patients of  196. Fifteen of  them (27.7 %) random-
ized fewer than 100 patients.
Table 1 shows the percentage of  articles that reported each individ-
ual item divided into publishing period groups. The numbers and per-
centages of  CONSORT items reported by >75% of  the articles by time 
period and by group are shown in Table 2.
During the whole examined period of  1998–2016, 14 items (36.8%) 
were found reported in >75% of  the articles, whereas the respective 
numbers for the 5-year periods were 11 (28.9%) in 1998–2004, 13 
(34.2%) in 2005–2009, and 17 (44.7%) in 2010–2016, showing a very 
small, insignificant increase in the reporting of  CONSORT items 
(p = 0.344).
The mean CONSORT compliance score was 56.5% (23.68–
84.21%). The RCTs that covered more than 75% of  the CONOSRT 
items (by time period) were as follows: 5 (9.25%); 1998–2004: 0; 2005–
2009: 3(15.79%); 2010–2016: 2 (7.69%). 
Reviewed by tle (n = 307)
Reviewed by abstract (n = 127) 
Reviewed by full text (n = 75)
Included in the study (n = 54)
Excluded as ineligible (n = 180)
Excluded as ineligible (n = 52)
Excluded as ineligible (n = 21)
Figure 1. Systematic Review Flowchart.
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1a 0.70 0.44 0.74 0.77
1b 0.81 0.78 0.79 0.85
Introduction
2a 1.00 1.00 1.00 1.00
2b 0.98 1.00 1.00 0.96
Methods
3a 0.78 0.56 0.84 0.81
3b 0.04 0.11 0.00 0.04
4a 0.94 0.89 0.89 1.00
4b 0.37 0.56 0.42 0.27
5 0.74 0.89 0.68 0.73
6a 0.69 0.44 0.79 0.69
6b 0.02 0.11 0.00 0.00
7a 0.69 0.44 0.58 0.85
7b 0.04 0.00 0.05 0.04
8a 0.46 0.33 0.53 0.46
8b 0.50 0.44 0.58 0.46
9 0.30 0.22 0.37 0.27
10 0.26 0.11 0.21 0.35
11a 0.39 0.44 0.37 0.38
11b 0.33 0.44 0.32 0.31
12a 0.96 1.00 1.00 0.92
12b 0.50 0.44 0.63 0.42
Results
13 0.70 0.44 0.68 0.81
13a 0.85 0.67 0.89 0.88
13b 0.78 0.56 0.74 0.88
14a 0.44 0.33 0.37 0.54
14b 0.02 0.00 0.05 0.00
15 0.81 0.89 0.79 0.81
16 0.54 0.11 0.53 0.69
17a 0.94 0.89 0.95 0.96
17b 0.13 0.11 0.16 0.12
18 0.41 0.22 0.47 0.42
19 0.87 0.78 0.89 0.88
Discussion
20 0.76 0.78 0.68 0.81
21 0.63 0.33 0.74 0.65
22 0.93 0.78 0.95 0.96
Other information
23 0.39 0.11 0.26 0.58
24 0.00 0.00 0.00 0.00
25 0.78 0.56 0.79 0.85
Discussion
The conclusion that this study seems to reach is that the reporting of  
RLS-related RCTs is far from optimal. Furthermore, it provides a gen-
eral view of  RLS RCTs and its methodological components.
The number and size of  RLS RCTs is smaller than that of  other 
neurological diseases. We included 54 RCT articles referring to 10,427 
randomized patients. In comparison to a recent similar study carried 
out by our group on the subject of  multiple sclerosis RCTs, we found 
103 studies regarding 42,031 patients21 for about the same time period 
(2000–2015). This is also made evident by the mean number of  patients 
randomized in these 53 studies, which was less than 200 (193).
Only 14 of  the 38 checklist items (36.8%) were addressed in 75% or 
more of  the studies published between 1998 and 2016. There was a 
slight increase in checklist item reporting between the three time peri-
ods. Some of  the underreported items were –in most cases – non- 
applicable (3b: important changes to methods; 6b: changes to trial 
outcomes; 7b: interim analyses and stopping guidelines). Other items 
underreported, though, contain important methodological informa-
tion regarding randomization (9: allocation concealment method – 
30%; 10: implementation – 26%). The allocation concealment 
method (concealment of  the allocated intervention at the time of  
enrollment) and implementation (who generated the allocation 
sequence, who enrolled participants, and who assigned participants to 
trial groups) is an important piece of  methodological information 
since trials in which the allocation sequence had been inadequately or 
unclearly reported yielded larger estimates of  treatment effects than 
trials in which authors adequately reported allocation conceal-
ment.13,32,34 Item 24 (where the full trial protocol can be accessed, if  
available) was the most underreported item (0%). The overall 
CONSORT compliance was generally found to be poor as well, with 
the mean compliance calculated to be 56.6%, which is considerably 
low and, sadly, not showing signs of  improvement over time. When 
considering the five usually not applicable items in RLS RCTs, an 
Table 2. >75% Compliance with the COSNORT Checklist per 





















3 (75) 3 (75) 3 (75) 4 (100)
Methods (17) 3 (17.6) 3 (17.6) 4 (23.5) 4 (23.5)
Results (11) 5 (45.5) 3 (27.3) 4 (36.4) 6 (54.5)
Discussion (3) 2 (66.6) 2 (66.6) 1 (33.3) 2 (66.6)
Other 
information (3)
1 (33.3) 0 (0) 1 (33.3) 1 (33.3)
Abbreviations: RCTs, randomized controlled trials.
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adjusted overall CONSORT compliance would be 71%, which is sim-
ilar with the one found in our study regarding multiple sclerosis (aver-
age CONSORT compliance 68.2%). This finding, though, should be 
regarded with some degree of  skepticism since not all studies included 
non-applicable items.
There are 585 journals currently endorsing CONSORT. In our 
study, 9 out of  21 journals that published RLS RCTs were CONSORT 
endorsers, and those articles’ compliance was larger – though insignifi-
cantly – than their non-endorsing counterparts (58.27% vs. 50.4%). At 
the same time, high impact factor journals had a better reporting, but it 
still did not reach the significance threshold.
The results of  this study must be interpreted with caution and some 
points need to be addressed. First, we used the 2010 revised 
CONSORT checklist for all RCTs regardless of  their publication date. 
Furthermore, the allocation of  a negative or positive response on the 
used checklist has not always been clear and straightforward, making 
it susceptible to subjectivity. In addition, most of  the CONSORT 
items have a title alongside a large paragraph of  explanation and 
information that should be used while reporting an RCT. The 
CONSORT checklist was made to help researchers report studies in a 
more thorough and detailed manner rather than being used as an eval-
uation tool. Consequently, the evaluation of  reporting is a more criti-
cal and delicate procedure.
Taking into consideration the aforementioned limitations and the 
data presented here, it is our feeling that RLS-related RCTs are in gen-
eral badly reported, regardless of  the time period, the quality of  the 
publishing journal, and its CONSORT endorsement. To the extent that 
reporting reflects study design and conducting, along with the fact that 
RLS RCTs are relatively small and few in number, while also regarding 
many different medicinal products, this study raises important concerns. 
RLS is a disease whose management is troublesome and tricky, and the 
related research seems to have many methodological pitfalls; hence, 
designing, performing, and reporting RCTs all need to be as detailed 
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